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Abstract Recent large-scale association studies have identi-
fied over 100 MS risk loci. One of these MS risk variants is
single-nucleotide polymorphism (SNP) rs17066096, located
~14 kb downstream of IL22RA2. IL22RA2 represents a com-
pelling MS candidate gene due to the role of IL-22 in autoim-
munity; however, rs17066096 does not map into any known
functional element. We assessed whether rs17066096 or a
nearby proxy SNP may exert pathogenic effects by affecting
microRNA-to-mRNA binding and thus IL22RA2 expression
using comprehensive in silico predictions, in vitro reporter
assays, and genotyping experiments in 6,722 individuals. In
silico screening identified two predicted microRNA binding
sites in the 3′UTR of IL22RA2 (for hsa-miR-2278 and hsa-
miR-411-5p) encompassing a SNP (rs28366) in moderate
linkage disequilibrium with rs17066096 (r2=0.4). The bind-
ing of bothmicroRNAs to the IL22RA2 3′UTRwas confirmed
in vitro, but their binding affinities were not significantly
affected by rs28366. Association analyses revealed significant
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association of rs17066096 and MS risk in our independent
German dataset (odds ratio =1.15, P=3.48×10−4), but did not
indicate rs28366 to be the cause of this signal. While our
study provides independent validation of the association
between rs17066096 and MS risk, this signal does not appear
to be caused by sequence variants affecting microRNA
function.
Keywords Genetic association . Immunogenetics .
Interleukin-22 .MiRNA . Luciferase reporter assay
Introduction
Multiple sclerosis (MS) is the most common auto-
inflammatory disease of the central nervous system and is
caused by an interplay of genetic and environmental risk
factors. Recent genome-wide association studies (GWAS)
and follow-up assessments have established more than 100
risk loci in MS [1–4], the majority of which point to a
predominant role of T cell-mediated immune mechanisms in
MS pathogenesis [1]. By design, single-nucleotide polymor-
phisms (SNPs) assessed in GWAS can be informative markers
tagging disease-associated regions, but often do not represent
the variants exerting a functional role, some may even be
located between genes. The identification of functional vari-
ants and the elucidation of underlying pathomechanisms will
thus be a major focus in MS genetics research in the coming
years.
One typical example is the MS risk locus on chromosome
6q23.3, in which rs17066096, the SNP most significantly
associated with MS risk (P=6.0×10−13)1, maps into an
intergenic region. The region surrounding this SNP contains
several potentially relevant immunological candidate genes:
rs17066096 is located ~14 kb downstream of IL22RA2 as well
as ~66 kb downstream of IFNGR1 and ~115 kb upstream of
IL20RA. A previous genetic association study [5] assessed 29
SNPs across IL22RA2 and IFNGR1 in Swedish subjects par-
tially overlapping with the original GWAS1 and concluded
that the association in this region was mostly driven by the 3′
end of IL22RA2. Supporting this conclusion, the same study
found no convincing evidence for an association between
SNPs in INFGR1 and MS risk [5].
Interleukin 22 (IL-22) is produced by proinflammatory T
helper cells and acts synergistically with IL-17 [6]. While the
exact role of the IL-22 pathway is not fully unraveled, it
appears to be highly relevant for the pathophysiology of
autoimmune diseases including MS [6, 7]. Given the emerg-
ing evidence for a pathogenic role of IL-22 in autoimmune
processes as well as the importance of small non-coding
microRNAs (miRNAs) for the regulation of gene expression
in MS (e.g. [8–10]), we set out to explore whether the MS
association signal at the 3′ end of IL22RA2 may be owing to
one or more functional sequence variants in or near miRNA
binding sites located in the IL22RA2 3′ untranslated region
(UTR). Such variants may alter the binding of certain
miRNA(s) to the mRNA 3′UTR and, as a result, the expres-
sion levels of IL22RA2. To assess this hypothesis, we per-
formed a comprehensive in silico assessment of the potential
role of DNA sequence variants onmiRNA-to-mRNAbinding.
This led to the identification of SNP rs28366 (which is in
linkage disequilibrium (LD)with the originalMSGWAS SNP
rs170660961) located in the seed region of a site predicted to
be bound by two miRNAs (hsa-miR-2278 and hsa-miR-411-
5p). Both SNPs were genotyped in a large German case-
control dataset (independent of the original GWAS1) compris-
ing 6,722 subjects. In parallel, we investigated the potential
role of rs28366 on the binding of both hsa-miR-2278 and hsa-
miR-411-5p to the IL22RA2 3′UTR in vitro using customized
luciferase reporter assays.
Methods
In silico assessments of IL22RA2 3’UTR SNPs predicted to
affect miRNA binding First, miRNA binding sites were pre-
dicted for 3′UTRs of all currently known protein-coding
IL22RA2 transcripts (downloaded from Ensembl Genes 67,
http://www.ensembl.org/biomart/martview) using miRanda v.
3.3a [11] (using the no-energy option), TargetScan 5.0 [12]
and PITA [13] and v18 of the mirBASE database (http://www.
mirbase.org). These predictions were performed with both the
reference and alternative alleles of known SNPs in this region
(based on build 137 of NCBI’s dbSNP; http://www.ncbi.nlm.
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nih.gov/SNP/). To ensure high sensitivity in identifying
miRNA binding sites, all potential miRNA binding sites
predicted by at least one of the three prediction programs
listed above [11–13] were included. Only SNPs displaying
at least moderate LD (i.e. r2 of 0.3; estimated from whole
genome sequence data of the 1000 Genomes phase 1 CEU
reference panel [14]) with rs17066096 were considered
further. Finally, we estimated the potential effect of each
eligible SNP on miRNA-to-mRNA binding using a modified
version [15] of the support vector regression (SVR) method
developed by Betel et al. [16].
Subjects The genetic association analyses of this study com-
prised 3,737 unrelated MS cases (71 % females) and 2,985
healthy control subjects (60 % females) of self-reported Eu-
ropean descent from Germany diagnosed according to stan-
dard diagnostic criteria (for further details see 2). All samples
were collected with informed written consent and appropriate
ethical approval at the respective sites.
Genotyping Rs17066096 and rs28366 were genotyped using
allelic discrimination assays based on TaqMan chemistry on a
7900HT Fast Real-Time PCR System (Life Technologies)
following the manufacturer's instructions. Each 384-well plate
contained approximately 5%CEUHapMap samples to assess
genotyping accuracy. Genotyping and genotype calling were
performed blind to phenotypic status.
Genetic association analysis Hardy–Weinberg equilibrium
(HWE) in controls was assessed using Pearson's χ2 as imple-
mented in PLINK v1.07 (http://pngu.mgh.harvard.edu/
purcell/plink/) [17]. All association analyses were based on
an additive transmission model and adjusted for age and sex
via logistic regression. Conditional logistic regression analysis
was performed for rs28366 while conditioning on
rs17066096. All reported P values are two tailed.
In vitro assessments of potential effects on miRNA-to-mRNA
binding via luciferase reporter assays A luciferase reporter
vector that contained the 3′UTR sequence of IL22RA2
(ENST00000296980) subcloned into the pLightSwitch_3UTR
vector 3′ of the Renilla luciferase gene along with miRNA
mimics for hsa-miR-2278 and hsa-miR-411-5p as well as non-
binding scrambled miRNA molecules were purchased from
SwitchGear Genomics (Menlo Park, CA, USA). The correct
orientation and the sequence of the reporter construct were
verified by Sanger sequencing. The construct containing the
alternative G instead of the reference A allele of rs28366 was
generated by site-directed mutagenesis, and the base change was
confirmed by Sanger sequencing. Two hundred ninety three
human embryonic kidney (HEK293) cells were cultured at
37 °C and 5 % CO2 in DMEM GlutaMax medium
(Invitrogen) with 10 % fetal bovine serum (Biochrom). Cells
were split in 96-well plates and after 24 h at 50 % confluency,
transfected with 50 ng plasmid and 50 nM miRNA using
DharmaFECT (ThermoScientific) according to the manufac-
turer’s instructions. The following transfection conditions were
used: (1) the reporter construct with the A (reference) allele of
rs28366 and scrambled miRNA, (2) the reporter construct with
the G (alternative) allele of rs28366 and scrambled miRNA, (3)
the reporter construct with the A allele and miRNA hsa-miR-
2278, (4) the reporter construct with the G allele and miRNA
hsa-miR-2278, (5) the reporter construct with the A allele and
miRNA hsa-miR-411-5p, 6) the reporter construct with the G
allele and miRNA hsa-miR-411-5p. Twenty four hours after
transfection, luciferase assays were conducted using the
LightSwitch assay reagents (SwitchGear Genomics) according
to the manufacturer’s instructions. Renilla luciferase intensity
values were recorded by endpoint reading with 3 s integration
time and 3,500 gain per well using a POLARStar Omega plate
reader (BMG Labtech). Ten independent experiments were per-
formed, using different cell batches and independent transfection
mixes. In each experiment, six wells were transfected per exper-
imental condition. The in vitro assay conditions had been opti-
mized previously based on an established miRNA-mRNA bind-
ing effect [18, 19], i.e. using co-transfections of the
pLightSwitch_3UTR vector containing the 3′UTR of APP
(ENST00000348990) with hsa-miR-101 in HEK293 cells, by
testing miRNA concentrations of 12.5 to 100 nM, 25 to 50 ng
vector, and endpoint readings 24 and 48 h post transfection. The
most stable miRNA binding effects without cytotoxicity were
observed using 50 nM miRNA, 50 ng vector, and endpoint
readings after 24 h and were subsequently used for the current
study as described above.
Statistical analysis of acquired in vitro data The statistical
analyses of the luciferase intensity data were performed in R
language (http://www.r-project.org) and based on a
framework for the analyses of luciferase experiments
introduced by Jacobs and Dinmann [20]: The
luciferase activity of the 3′UTR reporter construct
containing the A or G allele and co-transfected with a
functional miRNA was divided by the baseline lucifer-
ase activity of the reporter construct containing the A or
G allele, respectively, and co-transfected with the scram-
bled, non targeting miRNA as negative control. Outliers
were defined as quotients that deviated more than 1.5
times the fold spread (fold spread = third quartile - first
quartile) from the median as described in Jacobs and
Dinmann [20] and were subsequently excluded from
further analysis (applicable to one out of 236 data
points in this study). Next, the expression change of
the Renilla gene caused by substituting the A
(reference) allele with the G allele in the 3’UTR of
IL22RA2 was assessed based on the t test statistic for
two independent samples (Welch test).
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Results
Our in silico assessments identified two highly correlated
SNPs (rs28366 and rs202566, r2=0.92) in moderate LD with
rs17066096 (r2=0.40) that mapped within 80 bp of predicted
binding sites of 693 miRNAs in the 3′UTR of all three protein-
coding IL22RA2 transcripts (i.e. transcripts ENST00000296980
and ENST00000349184 [the 3′UTR sequences of which are
100 % identical], as well as ENST00000339602; Suppl.
Table 1). The modified SVR approach used to calculate the
difference in binding strength between 3′UTR sequences con-
taining the reference vs. alternative allele suggested that the
bindings of miRNAs hsa-miR-2278 and hsa-miR-411-5p to
transcript ENST00000296980 were most likely to be affected
by SNP rs28366 (a similar but slightly weaker effect on binding
was predicted for ENST00000339602). This SNP is located in
the seed regions of both predictedmiRNA binding sites (Fig. 1).
The alternative G allele allows for an additional Watson-Crick
binding in the seed region of the hsa-miR-2278 binding site,
which may increase the strength of the miRNA-to-mRNA
binding. For hsa-miR-411-5p, the predicted allele-specific ef-
fects on miRNA-to-mRNA binding were opposite to that of
hsa-miR-2278: here, the alternative G allele results in the dis-
ruption of aWatson-Crick pairing and the formation of a weaker
wobble base pair instead. As a result, this may decrease
the binding strength of hsa-miR-411-5p to its target
mRNA. The predicted effects on miRNA-to-mRNA
binding of the second SNP, rs202566, were overall
much less compelling than for rs28366; therefore, this
SNP was not considered further.
Next, we genotyped SNPs rs17066096 (originally identi-
fied by GWAS1) and rs28366 (potentially affecting miRNA-
to-mRNA binding) in a large German case-control dataset that
was independent of the original study [1]. The aims of these
analyses were to (1) independently validate the association
between IL22RA2 and MS risk in this dataset and (2) to assess
whether or not the association at rs17066096 is entirely or in
part due to rs28366. Importantly, rs28366 was not assessed in
the previous GWAS analysis [1] (data available to the au-
thors); thus, this signal may have been missed before. In our
dataset, genotyping efficiencies for rs17066096 and rs28366
were 99.1 and 98.7 %, respectively, and genotyping accuracy
was 100 % for both SNPs. Genotypes for both SNPs were
distributed according to HWE in control subjects (P=0.155
and 0.141, respectively). Logistic regression analyses con-
firmed the association of rs17066096 and MS risk (odds ratio
(OR) [95 % confidence interval (CI)]=1.15 [1.07-1.25], P=
3.48×10−4) showing the same directionality as reported in the
original study [1] (i.e., risk increase conferred by the
alternative G allele). In contrast, rs28366 demonstrated a
smaller effect size estimate (OR [95 % CI]=1.10 [1.02-
1.20]) and statistically weaker evidence for association
(P=0.0209) with MS susceptibility (Table 1). To assess
whether rs28366 may exert an effect on MS risk inde-
pendently of rs17066096, we repeated analyses for
rs28366, this time conditioning on rs17066096. Howev-
er, these analyses did not reveal evidence of genetic
association of rs28366 independent of rs17066069 (OR
[95 %CI]=0.99 [0.88-1.11], P=0.813; Table 1).
In parallel to the genetic association analyses, we assessed
whether our in silico predictions that (1) hsa-miR-2278 and
hsa-miR-411-5p bind to the 3′UTR of the IL22RA2 mRNA
molecule, and that (2) the presence of rs28366 affects the
binding of both miRNAs to their target sites, could be ob-
served in vitro using customized luciferase reporter assays.
While these experiments clearly show that both miRNAs bind
to reporter constructs containing the full-length 3′UTR of
IL22RA2 (as evidenced by significant reduction of luciferase
luminescence in experiments co-transfecting the reporter con-
structs with either miRNA compared to the co-transfection
with a non-binding negative miRNA control); this binding
was not affected by the allele status at rs28366 in the reporter
constructs (P=0.144 and P=0.473 for hsa-miR-2278 and hsa-
miR-411-5p, respectively, based on 10 experiments with 6
replicates each; Fig. 2). Overall, these results are in line with
our genetic association data indicating that rs28366 is not the
causal variant underlying the association signal between MS
Fig. 1 Predicted miRNA binding sites in the IL22RA2 3′UTR possibly
affected by rs28366. SNP rs28366 is located in the seed region (highlighted
in blue) of two predictedmiRNA target sites (formiRNAs hsa-miR-2278 and
hsa-miR-499b-5p) for all three protein-coding transcripts of IL22RA2 (shown
here: ENST00000296980). The alternative G allele of rs28366 (highlighted
in red) may alter binding affinity of hsa-miR-2278/hsa-miR-499b-5p to the
IL22RA2 3′UTR and subsequently alter IL22RA2 mRNA stability and/or
protein levels.
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risk and the IL22RA2 containing region on chromosome
6q23.3.
Discussion
In this study, we performed a “functional mapping” of the
previously identified association signal near IL22RA2 with
MS risk. Specifically, we tested the hypothesis that the
IL22RA2 association—which was previously suggested to
originate from near the 3′ end of IL22RA2 [1, 5]—may exert
its pathogenetic effects by affecting miRNA-to-mRNA bind-
ing and, therefore, expression of IL22RA2. While our com-
prehensive in silico and in vitro assessments successfully
identified two novel miRNA binding sites in the 3′UTR of
IL22RA2, the binding of either miRNAwas not affected by the
presence of rs28366 in vitro. Thus, this SNP does not appear
to represent a functional variant underlying the MS associa-
tion signal in this region. This conclusion was further support-
ed by the observation that the nominally significant MS asso-
ciation signal exerted by rs28366 was much weaker and
dependent of that observed for rs17066096 in our German
case-control dataset. Thus, in light of this comprehensive in
silico and in vitro assessments, it currently appears unlikely
that the functional basis of this association is due to major
effects of DNA sequence variants on miRNA-regulated ex-
pressional regulation of IL22RA2.
One possible limitation of our study relates to the fact that
all functional experiments were based on reporter assays
applied to HEK293 cells. This model system may not suffi-
ciently mirror physiologic conditions inMS effector cells such
as Th17. Thus, our overall negative findings do not entirely
exclude the presence of subtle miRNA-mediated SNP effects
in IL22RA2 in MS relevant cells. However, our negative
functional data are corroborated by our genetic association
results with rs28366, making it unlikely that this SNP exerts a
strong and clinically relevant effect on miRNA-to-mRNA
binding.
The results of this study, however, do not exclude the
possibility that IL22RA2 is, indeed, the functional gene at this
locus. While a recent international collaborative fine-mapping
effort of this region (using the Immunochip design [4]) did not
provide any additional information on the nature of the puta-
tive underlying functional variant, the possibility remains that
DNA sequence changes in the coding region of IL22RA2may





MAF (%) cases MAF (%) controls OR (95 % CI) P ORcond (95 % CI) Pcond
rs17066096 (C/T) 301/1488/1953 200/1078/1669 27.9 25.1 1.15 (1.07-1.25) 3.48×10−4 - -
rs28366 (G/A) 208/1306/2207 150/967/1825 23.1 21.5 1.10 (1.02-1.20) 0.0209 0.99 (0.88-1.11) 0.813
Association analysis of rs17066096 and rs28366 and MS risk was performed using logistic regression adjusted for age at examination, and sex and was
based on an additive model. Conditional logistic regression analysis of rs28366 andMS additionally included rs17066096 genotype status in the model.
minminor allele,majmajor allele,MAFminor allele frequency,OR (95%CI) odds ratio and 95% confidence interval (the reference allele with an OR of
1 corresponds to the major allele in all settings), cond conditional on rs17066096
Fig. 2 Influence of rs28366 (A/G allele) in the 3′UTR of IL22RA2 on
gene expression. This bar chart displays Renilla luciferase expression
under the control of the IL22RA2 3′UTR construct with the A (reference)
or G (alternative) alleles of rs28366 that was co-transfected with hsa-miR-
2278 and hsa-miR-411-5p, respectively, in HEK293 cells. Depicted are
the mean luciferase luminescence and standard errors relative to the
control luciferase luminescence of the IL22RA2 3′UTR construct co-
transfected with non-binding negative miRNA control (corresponding
to the horizontal line). The relative mean luciferase luminescence of the
construct containing the A and the G allele was 0.660 (±0.0393)
and 0.585 (±0.0321), respectively, for hsa-miR-2278 (P=0.144)
and 0.568 (±0.0296) and 0.593 (±0.0183), respectively, for hsa-
miR-411-5p (P=0.473).
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play a role in this setting. Alternatively, the association could
be explained by SNPs in the 5′UTR or more distant upstream
regulatory regions potentially affecting IL22RA2 expression
via effects on mRNA transcription.
In summary, our study provides independent genetic evi-
dence supporting that IL22RA2 (or a gene nearby) is signifi-
cantly associated with MS risk. Functionally, this association
is unlikely caused by impaired miRNA-related expressional
regulation of IL22RA2. Further studies are needed to elucidate
potential alternative pathophysiological mechanisms underly-
ing this association.
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